Your session is about to expire
← Back to Search
Imsidolimab for Generalized Pustular Psoriasis (GEMINI2 Trial)
GEMINI2 Trial Summary
This trial is testing a new drug for people with a certain type of psoriasis. The goal is to see if it is safe and effective.
GEMINI2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.GEMINI2 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My doctor thinks long-term GPP treatment is right for me.
- Group 1: SC Imsidolimab
- Group 2: IV +SC Imsidolimab
- Group 3: SC Placebo
- Group 4: Standard of Care
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the largest amount of people that can be in this trial?
"That is correct, the online clinicaltrial database lists this trial as recruiting. This particular trial was first posted on 4/21/2022 and was last updated on 9/12/2022. Currently, the study is looking for 45 individuals willing to participate at 6 different locations."
Where are the sites for this trial?
"There are a total of six locations where this trial is currently taking place. They are situated in Largo, Ann Arbor, Dallas and other, as yet unnamed, cities. It would be beneficial for you to choose the location closest to you to cut down on travel if you decide to take part in the trial."
What are the requirements for joining this clinical trial?
"Up to 45 individuals aged 18 to 80 that have been diagnosed with generalized pustular psoriasis (gpp) are eligible for this clinical trial. Key inclusion criteria include: the patient must have participated in the preceding placebo-controlled Phase 3 study ANB019-301 and completed the Week 1 visit without needing rescue/prohibited medication for GPP, and the patient must be a candidate for prolonged GPP treatment according to the Investigator's judgment."
If a patient is over 35, are they still eligible for this program?
"This specific trial requires that patients be aged between 18-80, which is a more restrictive age range than the average trial (32 for those under 18 and 154 for those over 65)."
Does SC Imsidolimab have any known negative effects on patients?
"SC Imsidolimab has undergone multiple clinical trials with supportive data, meaning it is a safe medication with a score of 3."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What questions have other patients asked about this trial?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger